Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
Title:
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
Author:
Ribaldone, Davide Giuseppe Parisio, Laura Variola, Angela Bossa, Fabrizio Castiglione, Fabiana Marzo, Manuela Piazza, Nicole Aratari, Annalisa Savarino, Edoardo Vincenzo Bodini, Giorgia Mastronardi, Mauro Micheli, Federica Mazzuoli, Silvia Ascolani, Marta ViganĂ², Chiara Cappello, Maria Bezzio, Cristina Ciccocioppo, Rachele Scardino, Giulia Sarli, Ennio Pugliese, Daniela Scaldaferri, Franco Napolitano, Daniele Todeschini, Alessia Geccherle, Andrea Colaci, Nicoletta Guerra, Maria Annese, Monica Testa, Anna Caiazzo, Anna Conforti, Francesco Simone Festa, Stefano Lorenzon, Greta Marra, Antonella Magiotta, Ambra Baccini, Flavia Amato, Arnaldo Poshnjari, Anxhela Vernero, Marta Caprioli, Flavio Caviglia, Gian Paolo